Drugs / GNR-127
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07155499 | Oct 2024 → May 2025 overdue | seasonal allergic rhinitis | AO GENERIUM | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07155499 ↗ |
| Modality | Vaccine | “The investigational product GNR-127 is a recombinant vaccine” NCT07155499 ↗ |
| Route | Subcutaneous | “GNR-127, 20 mcg, suspension for subcutaneous administration” NCT07155499 ↗ |